Literature DB >> 8988470

The implementation of telemedicine within a community cancer network.

J W London1, D E Morton, D Marinucci, R Catalano, R L Comis.   

Abstract

Telemedicine is being used by physicians at the member hospitals of the Jefferson Cancer Network (JCN) for consultations regarding the diagnosis and management of cancer patients. The technology employed for this telemedicine system was chosen to meet three related specifications: low capital and operating cost, internal maintainability by community hospital data processing staffs, and compatibility with the existing technologic infrastructure. The solution selected is the ubiquitous desktop personal computer and associated software, and Integrated Services Digital Network (ISDN) communications links. The overall performance of this technology has been very satisfactory; ISDN communications has sufficient bandwidth for the transfer of patient data, including text reports, radiographs, and pathology slide images. The presence of the radiologist's interpretation along with the radiographic images allows the presentation of the images on these systems to be acceptable for review purposes. The video frame rates of these systems (12 to 15 frames per second) is adequate, particularly given the "talking heads" nature of the video presentations. Furthermore, the quality of the video image (resolution, size, frame rate) is secondary to the quality of the presentation of the medical information displayed and the capability for mutual annotation of the patient data during the consultation.

Entities:  

Mesh:

Year:  1997        PMID: 8988470      PMCID: PMC61194          DOI: 10.1136/jamia.1997.0040018

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  6 in total

Review 1.  Diffusion and adoption of state-of-the-art therapy.

Authors:  L Ford; A D Kaluzny; E Sondik
Journal:  Semin Oncol       Date:  1990-08       Impact factor: 4.929

2.  Digitised video and the care of outpatients with cancer.

Authors:  M Lipsedge; A B Summerfield; C Ball; J P Watson
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

3.  Using a community clinical trials network for treatment, prevention, and control research: assuring access to state-of-the-art cancer care.

Authors:  A D Kaluzny; R Warnecke; L M Lacey; T Johnson; D Gillings; H Ozer
Journal:  Cancer Invest       Date:  1995       Impact factor: 2.176

4.  Displaying radiologic images on personal computers.

Authors:  T Gillespy; A H Rowberg
Journal:  J Digit Imaging       Date:  1993-08       Impact factor: 4.056

5.  Patient satisfaction with telemedicine in a rural clinic.

Authors:  A Allen; J Hayes
Journal:  Am J Public Health       Date:  1994-10       Impact factor: 9.308

Review 6.  Barriers to clinical trials. Part III: Knowledge and attitudes of health care providers.

Authors:  E G Mansour
Journal:  Cancer       Date:  1994-11-01       Impact factor: 6.860

  6 in total
  5 in total

1.  A DBMS-based medical teleconferencing system.

Authors:  J Chun; H Kim; S Lee; J Choi; H Cho
Journal:  J Am Med Inform Assoc       Date:  2001 Sep-Oct       Impact factor: 4.497

Review 2.  The basis for using the Internet to support the information needs of primary care.

Authors:  E E Westberg; R A Miller
Journal:  J Am Med Inform Assoc       Date:  1999 Jan-Feb       Impact factor: 4.497

3.  Telehealth: the need for evaluation.

Authors:  D R Masys
Journal:  J Am Med Inform Assoc       Date:  1997 Jan-Feb       Impact factor: 4.497

4.  A telemedicine application to schedule temperature in an in vivo sensor network for cancer treatment.

Authors:  Rossi Kamal; Choong Seon Hong; Seok-Geun Lee
Journal:  Telemed J E Health       Date:  2012-12       Impact factor: 3.536

5.  Feasibility study of multidisciplinary oncology rounds by videoconference for surgeons in remote locales.

Authors:  Anna Gagliardi; Andy Smith; Vivek Goel; Denny DePetrillo
Journal:  BMC Med Inform Decis Mak       Date:  2003-06-19       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.